News Novartis takes Xolair follow-up into phase III hives trial Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, into a phase III programme on the strength of a mid-stage study.
News AZ seeking $1.5bn in savings by end-2029 AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
